Neumora Therapeutics Q2 EPS Forecast Boosted by Analyst

HC Wainwright analyst raises Q2 2026 earnings estimates for the biotech firm.

Apr. 2, 2026 at 11:36am

Got story updates? Submit your updates here. ›

Neumora Therapeutics, a clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system disorders, received a boost to its Q2 2026 earnings per share (EPS) forecast from HC Wainwright analyst D. Tsao. The analyst increased the EPS estimate from ($0.36) to ($0.30), citing the company's progress in its product pipeline.

Why it matters

Neumora Therapeutics is a promising biotech firm in the highly competitive and rapidly evolving field of neurological and psychiatric drug development. Positive analyst forecasts can influence investor sentiment and potentially drive stock price movements, which is significant for a clinical-stage company like Neumora that is still working to bring its pipeline of treatments to market.

The details

In a research note issued on March 31st, HC Wainwright analyst D. Tsao increased his Q2 2026 EPS estimate for Neumora Therapeutics from ($0.36) to ($0.30). The analyst also provided updated estimates for the company's Q3 2026 ($0.32 EPS), Q4 2026 ($0.30 EPS), and full-year 2026 ($1.29 EPS), as well as projections for subsequent years through 2030.

  • The research note was issued on Tuesday, March 31st.

The players

D. Tsao

An analyst at HC Wainwright who covers Neumora Therapeutics.

Neumora Therapeutics

A clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system disorders.

HC Wainwright

An investment banking and securities firm that provides research coverage on Neumora Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“HC Wainwright analyst D. Tsao now anticipates that the company will earn ($0.30) per share for the quarter, up from their prior forecast of ($0.36).”

— D. Tsao, Analyst

The takeaway

The increased Q2 2026 EPS forecast from a respected analyst is a positive sign for Neumora Therapeutics, as it suggests the company's drug development efforts are progressing well and could lead to improved financial performance in the coming years. This news may help boost investor confidence in the biotech firm's long-term potential.